According to FutureWise analysis the market for Somatostatin Analogs in 2023 is US$ 7 billion, and is expected to reach US$ 13.17 billion by 2031 at a CAGR of 8.20%.
Somatostatin, a protein naturally produced in the body, is called. The hypothalamus and stomach are important organs for the production of somatostatin. Somatostatin reduces hormone production, including many gut hormones. It also controls the release of other hormones from the pancreas as well as growth hormones. Somatostatin analogs reduce the body's production of too many hormones and decrease symptoms such as carcinoid syndrome. They also slow down the growth of tumors. Somatostatin analogs stop excessive hormone production in the body. The most commonly treated indications with somatostatin analogs are neuroendocrine tumors (NETs), and Acromegaly. Acromegaly is a rare hormonal disorder. Other common tumors that can be treated with Somatostatin Analogs include carcinoid tumors and glucagonomas, VIPomas, and GH-secreting tumors. Somatostatin Analogs can also be used to treat Cushing syndrome. Somatostatin, a hormone naturally found in the body, is produced by the hypothalamus, other tissues of the digestive tract, and the pancreas. It is responsible for inhibiting the release of excessive growth hormone from the anterior pituitary, pancreas, and insulin glands. It prevents the release of hormones, regulates activity in the GI tract, and controls the reproduction of normal and tumor cells. Somatostatin is also a neurotransmitter within the nervous system.
When somatostatin regulation becomes unbalanced, it can lead to high levels of hormones produced by neuroendocrine tumors (NETs). This further increases the risk of developing carcinoid syndrome. People with carcinoid syndrome have found that somatostatin analogs can be effective. Somatostatin analogs have been proven effective in the treatment and prevention of acromegaly. They are effective in relieving symptoms of carcinoid syndrome, such as diarrhea and skin flushing. They are also able to regulate most gastrointestinal hormones, reduce pancreatic secretion and gastric acid, and can help reduce bleeding from esophageal varices. Somatostatin analogs are available commercially for over three decades. Previously, the market for somatostatin analogs was dominated mainly by Novartis and Ipsen. The market has changed over the last few years, as there is more demand for these drugs. The development of novel and generic somatostatin analogs is now being undertaken by a variety of actors. The first line of treatment for many conditions, including acromegaly and carcinoid syndrome, Cushing, and others, is man-made somatostatin (synthetic). Somatostatin analogs inhibit the production of growth hormones and serotonin. Carcinoid syndrome is caused by high levels of hormones produced by neuroendocrine tumors (NETs). It is responsible for controlling symptoms of carcinoid syndrome, including skin flushing or diarrhea. People with carcinoid syndrome may be able to receive somatostatin analogs. Somatostatin analogs can slow down or stop hormones like insulin and gut hormones. Somatostatin analogs regulate stomach emptying and intestinal function.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Somatostatin Analogs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Somatostatin Analogs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.